[go: up one dir, main page]

EP4337204A4 - COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER - Google Patents

COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER

Info

Publication number
EP4337204A4
EP4337204A4 EP22808332.5A EP22808332A EP4337204A4 EP 4337204 A4 EP4337204 A4 EP 4337204A4 EP 22808332 A EP22808332 A EP 22808332A EP 4337204 A4 EP4337204 A4 EP 4337204A4
Authority
EP
European Patent Office
Prior art keywords
bisfluoralkyl
cancer
treatment
compositions containing
benzodiazepinone compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22808332.5A
Other languages
German (de)
French (fr)
Other versions
EP4337204A1 (en
Inventor
Joel Kaye
Rami RAUCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ayala Pharmaceuticals Inc
Original Assignee
Ayala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayala Pharmaceuticals Inc filed Critical Ayala Pharmaceuticals Inc
Priority claimed from PCT/US2022/028956 external-priority patent/WO2022241095A1/en
Publication of EP4337204A1 publication Critical patent/EP4337204A1/en
Publication of EP4337204A4 publication Critical patent/EP4337204A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22808332.5A 2021-05-13 2022-05-12 COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER Pending EP4337204A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187991P 2021-05-13 2021-05-13
US202163214355P 2021-06-24 2021-06-24
PCT/US2022/028956 WO2022241095A1 (en) 2021-05-13 2022-05-12 Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer

Publications (2)

Publication Number Publication Date
EP4337204A1 EP4337204A1 (en) 2024-03-20
EP4337204A4 true EP4337204A4 (en) 2025-04-16

Family

ID=89898822

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22808332.5A Pending EP4337204A4 (en) 2021-05-13 2022-05-12 COMPOSITIONS CONTAINING BISFLUORALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF CANCER

Country Status (2)

Country Link
US (1) US20240299411A1 (en)
EP (1) EP4337204A4 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019215585A1 (en) * 2018-05-06 2019-11-14 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763956B2 (en) * 2012-06-19 2017-09-19 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20210040050A1 (en) * 2018-05-06 2021-02-11 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763956B2 (en) * 2012-06-19 2017-09-19 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
US20200179511A1 (en) * 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20210040050A1 (en) * 2018-05-06 2021-02-11 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022241095A1 *
WANG JING ET AL: "APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 51, no. 2, 6 June 2017 (2017-06-06), GR, pages 563 - 572, XP093008035, ISSN: 1019-6439, DOI: 10.3892/ijo.2017.4028 *

Also Published As

Publication number Publication date
EP4337204A1 (en) 2024-03-20
US20240299411A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
EP3983433A4 (en) NOVEL INTERLEUKIN-2 VARIANTS FOR CANCER TREATMENT
EP4337329A4 (en) COMBINATIONS FOR THE TREATMENT OF CANCER
EA201990495A1 (en) BIARY COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
EP4017489C0 (en) DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS
EP4352042A4 (en) Compounds for the treatment of SARS
EA201990221A1 (en) 1,3-DIHYDROXIPHENYL DERIVATIVES APPLICABLE AS IMMUNOMODULATORS
EP3823653A4 (en) PROGRAMMABLE BACTERIA FOR THE TREATMENT OF CANCER
EP3589289A4 (en) INHIBITION OF SMARCA2 FOR TREATMENT OF CANCER
EP4085144A4 (en) COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA
EP3793544C0 (en) BIFUNCTIONAL COMPOSITIONS FOR TREATING CANCER
EP3490543A4 (en) ASCORBIC ACID, CHINONE COMPOUND AND SODIUM GLUCOSE-COTRANSPORTER INHIBITOR FOR TREATING CANCER
EP3576792A4 (en) PROCEDURES, COMPOSITIONS AND KITS FOR TREATMENT OF CANCER
EP3947460A4 (en) MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
EP4096675C0 (en) Compositions for the treatment of long COVID
EP4259639A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP4003351A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP4151227A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
EP4259638A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP4178574A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASES AND CANCER
EP3471774A4 (en) PORPHYRINE COMPOUNDS AND COMPOSITIONS FOR TREATING CANCER
EP3708173C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING MIRNA-3140 FOR THE TREATMENT OF CANCER
EP4096653A4 (en) COMPOSITIONS FOR TREATING ANGIOLIPOMA
EP3969001A4 (en) BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF NOTCH-ACTIVATED BREAST CANCER
EP4422608A4 (en) Endoxifen for the treatment of cancer
EP4058041C0 (en) COMPOSITION FOR THE TREATMENT OF EPITHELIAL LESIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250314

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 243/14 20060101ALI20250310BHEP

Ipc: A61K 31/635 20060101ALI20250310BHEP

Ipc: A61K 31/5513 20060101ALI20250310BHEP

Ipc: A61K 31/44 20060101AFI20250310BHEP